advertisement
About Advertising Industry

BNET Advertising provides daily industry trends and news coverage with insights for managers and executives about the major agencies in advertising, marketing, and public relations. In addition to detailed company and agency profiles, we bring you detailed industry analysis on new partnerships and acquisitions, ad buying and cost, new investments, inventory issues, and other issues critical to the marketing sector.

14 Drug Companies Cited for Misleading Google Ads

By Jim Edwards | Apr 7, 2009

The FDA cited 14 drug companies for misleading advertising in sponsored ads among Google search results.

Those cited: Biogen Idec, Sanofi Aventis, GlaxoSmithKline, Forest Laboratories, Cephalon, Bayer, Johnson & Johnson, Pfizer, Novartis , Genentech, Boehringer Ingelheim, Merck, Hoffman-LaRoche, and Eli Lilly.

The citations, sent as letters to drug companies, signify that the FDA is no longer going to ignore the online promotion of drugs. For years, the FDA focused its regulatory attention on TV and print ads. While most drug companies have approached the web in a conservative fashion, there have been some outlandish experiments, including online video games.

Companies lulled themselves into a false sense of security over the years because their web sites have usually been so much richer than their TV ads. The sites often include all the prescribing information and pages of warnings and side effect descriptions. This level of detail, companies felt, kept them in line with the FDA’s requirements for the “fair balance” about drug risks that is required in all advertising.

To the companies’ likely chagrin, the FDA has targeted them for the sponsored links they run on Google — the form of online advertising that is least able to deliver a balance of claims and risks.

Sponsored links usually include only the name of the web site followed by less than a dozen words. In the case of the 14 cited drug companies, those words all contained promotional and efficacy messages — and none contained risk information.

Bayer’s Levitra is an example. When searched in Google, the sponsored link says only:

Poor Blood Flow & ED; Blood Flow May Decrease With High Blood Pressure And May Lead to ED

FDA told Bayer:

The sponsored links cited in this letter are misleading because they make representations and/or suggestions about the efficacy of Levitra, YAZ, and Mirena, but fail to communicate any risk information associated with the use of these drugs.

Pfizer got one for Chantix too:

CHANTIX from Pfizer; Learn about CHANTIX, an aid for smoking cessation treatment.

You can download all the letters and screen grabs of the offending ads here.

Ad Age noted that Sanofi-Aventis (cited for a Plavix ad) isn’t taking this lying down:

Sanofi-Aventis believes that the links were consistent with DDMAC requirements for the provision of risk information … The links went to the product-specific website, which contains the important risk information on the landing page and a link to the full prescribing information.

It all begs the question: What are companies supposed to have those lines of text say?

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • FDA cracks down on search-engine ads

    Fierce Pharma - 215 days 20 hours 50 minutes ago

    Everybody knows Internet advertising is hot. Traditional media is watching its share of ad dollars decline again and again. Meanwhile, the digital domain's share is growing. Right now, pharma has between 5 percent and 10 percent of their marketing budgets in digital, and the share is growing, DMNews notes. But Internet advertising has its...

  • Pharma invests $28.8M in Q2 lobbying$

    Fierce Pharma - 109 days 22 hours 55 minutes ago

    Drugmakers continue to pour dollars into Washington coffers as the debate over healthcare reform shows no sign of stopping. New numbers from lobbying reports filed yesterday show that PhRMA ploughed $6.2 million into lobbying during the second quarter. Pfizer spent more than any other individual drugmaker at $5.6 million. As the Washington Post...

  • Back your fave M&As in Merger Madness

    Fierce Pharma - 235 days 20 hours 44 minutes ago

    For the irrepressible matchmakers among you, we offer the Wall Street Journal Health Blog's annual March Madness bracket, pharma-style. This time, the subject is--yes--M&A. The blogsters have paired the engaged couples--Pfizer/Wyeth, Roche/Genentech, Eli Lilly/ImClone, Merck/Schering-Plough--and put together the wallflowers, too. So Johnson &...

  • Rituximab filed in US for common leukaemia

    Scrip News - 171 days 21 hours 28 minutes ago

    Genentech ( Roche) and Biogen Idec have filed two supplemental BLAs with US FDA for their blockbuster non-Hodgkin's lymphoma (NHL) drug Rituxan (rituximab) to treat both previously untreated and treated chronic lymphocytic leukaemia (CLL), the most

  • Genentech, Biogen ask FDA to broaden Rituxan use

    Fierce Pharma - 171 days 22 hours 57 minutes ago

    Genentech and partner Biogen Idec are asking the FDA to allow their cancer drug Rituxan to be used in combination with chemotherapy for people with chronic lymphocytic leukemia. Report More information about formatting options

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement